Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dymista for exercise-induced airway obstruction in asthmatic adolescents with allergic rhinitis
NL-OMON48838Phase 4Completed
- Sponsor
- Medisch Spectrum Twente
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fluticasone propionate in allergic rhinitis (AR) and asthma (2 arms), sponsored by Medisch Spectrum Twente. Primary endpoints: Reduction in exercise-induced fall in FEV1 and Reduction in exercise-induced fall in MIF50. Started Apr 2019; status: completed.
02
Drugs
fluticasone propionate
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on NL-OMON48838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48838.